Biogen’s Alzheimer’s Drug Slows Mental Decline in Early Study
Black News, Commentary and Culture | The Washington Informer
Biogen shares were up 6.5 percent, or $27.97, at $461.92 in morning trading, after rising as high as $480.18. Biogen is entering a field littered with expensive failures from such drug makers as Pfizer Inc and Eli Lilly and Co. Lilly and Roche Holding AG are both conducting trials on drugs that work the same way as Biogen’s, by blocking beta amyloid, a protein that forms toxic brain plaques that are theoretically an underlying cause of the degenerative brain disease.